(NASDAQ: ASND) Ascendis Pharma A's forecast annual revenue growth rate of 43.91% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.48%, and while it is forecast to beat the US market's average forecast revenue growth rate of 24.03%.
Ascendis Pharma A's revenue in 2026 is $857,300,000.On average, 18 Wall Street analysts forecast ASND's revenue for 2026 to be $87,957,987,096, with the lowest ASND revenue forecast at $71,937,725,664, and the highest ASND revenue forecast at $98,392,640,136. On average, 18 Wall Street analysts forecast ASND's revenue for 2027 to be $124,417,892,424, with the lowest ASND revenue forecast at $93,911,877,360, and the highest ASND revenue forecast at $152,652,835,944.
In 2028, ASND is forecast to generate $155,783,231,856 in revenue, with the lowest revenue forecast at $119,323,326,528 and the highest revenue forecast at $198,442,548,696.